Last reviewed · How we verify
Cancer — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Fludeoxyglucose F-18 | FLUDEOXYGLUCOSE | Downstate Clincl | Radioactive Diagnostic Agent [EPC] | 2020-01-01 | ||
| Fludeoxyglucose F-18 | F-18 | 3D Imaging Drug | Radioactive Diagnostic Agent [EPC] | 2015-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- 3D Imaging Drug · 1 drug in Cancer
- Downstate Clincl · 1 drug in Cancer
- Pfizer Inc. · 1 drug in Cancer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Cancer:
Cite this brief
Drug Landscape (2026). Cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cancer. Accessed 2026-06-09.
Related
- Cancer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing